ClinicalTrials.gg
DrugBiological

Ravulizumab clinical trials

Also written Ultomiris and ALXN1210.

studies test it
39
open now
8
in phase 3
25
first study started
2014

How each study uses ravulizumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the ravulizumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
21 Dec 2018 · ULTOMIRIS · BLA 761108 (FDA, Drugs@FDA)
European Union
2 Jul 2019 · Ultomiris · EMEA/H/C/004954 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Ravulizumab
38

Brand

Ultomiris
23

Development codes

ALXN1210
21

Studies by the year they started

38 studies that test it; most in 2020 (6); 1 more planned to start later

Studies that test ravulizumab, by start year
YearStudies
20141
20152
20164
20173
20182
20193
20206
20214
20222
20232
20242
20253
20264

Who runs them

Industry 35 · Other 4

Alexion Pharmaceuticals, Inc. (34) · Mayo Clinic (1) · Massachusetts General Hospital (1) · Regeneron Pharmaceuticals (1) · Brigham and Women's Hospital (1) · Cambridge University Hospitals NHS Foundation Trust (1)

Often tested with

Tested in the same studies.

Eculizumab (3) · Satralizumab (1) · Inebilizumab (1) · Baricitinib (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 4, 2 in phase 3

Studies that test ravulizumab, phase 3 first.

Studies

Open first, then newest update. How each study uses ravulizumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 39

See all 39 studies that test ravulizumab →

Given beside what is tested · 3 — ravulizumab is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with ravulizumab

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call ravulizumab · ClinicalTrials.gg INT001020

  • MeSH (NLM) C000629409ravulizumabConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) C3VX249T6LRAVULIZUMABConfirmed FDA, NLM, Wikidata
  • RxNorm 2107301Confirmed FDA, Wikidata
  • Wikidata Q55641547ravulizumabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C124657RavulizumabOne source FDA
  • DrugBank DB11580One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.